WESTLAKE VILLAGE, Calif., and DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will present new data from its clinical development program and marketed ZORYVE® (roflumilast) portfolio during the 2026 American Academy of Dermatology (AAD) Annual Meeting taking place March 27-31 in Denver. In an AAD late-breaking podium presentation, t ...

Core Insights - Ally Bridge Group NY LLC has acquired a new position in Arcutis Biotherapeutics, purchasing 233,220 shares valued at approximately $4.396 million, representing about 2.7% of its total holdings, making it the 13th largest position in their portfolio [2] - Several institutional investors have also increased their stakes in Arcutis Biotherapeutics, with notable increases from Jones Financial Companies Lllp (1,291.1% increase) and PNC Financial Services Group Inc. (10.2% increase) [3] - Insiders have sold a total of 175,233 shares worth $4.537 million over the last 90 days, with 9.40% of the stock currently owned by corporate insiders [4] Financial Performance - Arcutis Biotherapeutics reported earnings of $0.13 per share for the last quarter, exceeding the consensus estimate of $0.03 by $0.10, with revenues of $129.5 million, surpassing analyst expectations of $110.79 million [6] - The company has a market capitalization of $2.82 billion, a P/E ratio of -162.49, and a debt-to-equity ratio of 0.57 [5] Analyst Ratings - Analysts have issued positive ratings for Arcutis Biotherapeutics, with target prices raised by TD Cowen ($30 to $35), HC Wainwright ($30 to $34), and Needham & Company LLC ($31 to $36), all maintaining a "buy" rating [7] - The average rating for the stock is "Moderate Buy" with a consensus price target of $34.00 [7] Company Overview - Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for immuno-inflammatory skin diseases, employing a precision-medicine approach to improve treatment efficacy and tolerability [8]

Core Insights - Arcutis Biotherapeutics announced positive results from the Phase 3 open-label extension study of ZORYVE (roflumilast) cream 0.05% for treating mild-to-moderate atopic dermatitis in children aged 2 to 5 years, showing sustained efficacy and safety over 56 weeks [1][7][10] Study Results - The INTEGUMENT-OLE study demonstrated that ZORYVE cream 0.05% is safe and well-tolerated, with efficacy improving over time [1][7] - 63.1% of participants achieved a Validated Investigator Global Assessment score of Clear or Almost Clear at Week 56 [6] - 71.9% of children continuing treatment and 76.0% of those switching from vehicle to ZORYVE cream achieved at least a 75% reduction in Eczema Area and Severity Index [6][8] Safety Profile - Treatment-Emergent Adverse Events (TEAEs) were reported in 49.8% of participants, with most being mild or moderate [4] - Serious Adverse Events (SAEs) occurred in 3.2% of participants, none of which were treatment-related [4] - Over 97% of participants showed no evidence of local irritation, and severe burning or stinging sensations were reported in ≤1.8% of participants [5] Treatment Regimen - Children achieving clear skin were transitioned to a proactive twice-weekly application, maintaining disease control for a median duration of approximately 8 months [7][9] - The study included 562 participants who initially applied ZORYVE cream once daily, with 30.2% transitioning to the twice-weekly regimen [3][9] Industry Context - Atopic dermatitis affects approximately 9.6 million children in the U.S., highlighting the need for effective treatments in this demographic [2][11] - ZORYVE is recognized as the number one prescribed branded topical therapy for atopic dermatitis, seborrheic dermatitis, and plaque psoriasis [13]

Core Insights - Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is recognized as one of the 10 fastest growing NASDAQ stocks to buy [1] - The company has received positive price target adjustments from Guggenheim and TD Cowen, both raising their targets to $35 while maintaining a Buy rating, reflecting confidence in the company's growth trajectory and product commercialization efforts [2][3] Financial Performance - For Q4 2025, Arcutis reported an EPS of $0.13, exceeding the consensus estimate of $0.09, and Q4 revenue reached $129.5 million, surpassing the consensus of $113.03 million [3] - The company achieved over 90% year-over-year growth in net product revenue in 2025, driven by strong demand for its product ZORYVE and successful execution of multiple product launches [3] Growth Strategy - The CEO, Frank Watanabe, indicated that the company is entering a new growth phase with a solid cash position and resources to invest in the continued growth of ZORYVE and advancement of its pipeline [3]

Core Insights - Arcutis Biotherapeutics, Inc. has promoted Mas Matsuda to executive vice president, chief legal officer, and corporate secretary, reflecting the company's commitment to strengthening its legal and compliance framework as it continues to grow and commercialize its ZORYVE portfolio [1][2] Company Overview - Arcutis is a commercial-stage biopharmaceutical company focused on innovations in immuno-dermatology, with a growing portfolio of advanced targeted topicals approved for treating major inflammatory skin diseases [5][6] - The company has achieved significant commercial growth, including six FDA approvals for its ZORYVE product line, which addresses immune-mediated skin diseases [2][3] Leadership and Strategy - Mas Matsuda has been with Arcutis since January 2022, playing a crucial role in the company's legal and compliance strategy, and has been instrumental in the development and growth of the ZORYVE franchise [2][3] - The company is entering a new phase of growth, with Matsuda's leadership expected to be critical in expanding its commercial presence and advancing its product portfolio [2][3] Product Information - ZORYVE cream and foam are indicated for the treatment of various dermatological conditions, including atopic dermatitis and plaque psoriasis, in both pediatric and adult patients [7][8] - The product line includes different formulations with specific indications for various age groups, showcasing the company's commitment to addressing diverse patient needs [7][8]

Core Viewpoint - Arcutis Biotherapeutics is experiencing significant growth driven by its product ZORYVE, with strong revenue performance and strategic expansions in both dermatology and primary care sectors. Group 1: Company Strategy and Operations - The company is ending its primary care partnership to develop in-house primary care and pediatric sales capabilities, aiming to have a 30-person team operational by July 1 [1] - Arcutis plans to expand its dermatology sales force by 30 representatives, increasing the total to 160, to enhance engagement with mid-decile prescribers while maintaining relationships with high-decile prescribers [2] - The initial primary care build is characterized as a "pilot" that can be scaled if successful [1] Group 2: Product Performance and Market Position - ZORYVE is positioned as a conversion product away from topical steroids, with 24 million topical prescriptions in dermatology, where topical steroids account for 64% of prescriptions [3] - The fourth-quarter net revenue reached $127.5 million, representing a 29% quarter-over-quarter growth, with all products in the portfolio showing growth [4][5] - ZORYVE foam constitutes about 50% of the business, with expected growth across all formulations, particularly in atopic dermatitis [6] Group 3: Pediatric Expansion and Pipeline Developments - Arcutis anticipates approval for ZORYVE in plaque psoriasis for ages 2–5 by the end of June and plans to file an NDA for atopic dermatitis in infants aged 3–24 months [7] - The company is conducting Phase II studies for additional uses of ZORYVE, including hidradenitis suppurativa and vitiligo, with results expected in Q4 [9] Group 4: Financial Health and Intellectual Property - Arcutis reached cash flow breakeven in the previous quarter and expects to maintain this status, having added $26 million to its cash reserves [13] - The company holds 27 issued U.S. patents for ZORYVE, with coverage extending through 2042 for the foam and 2037 for the cream [12] Group 5: Market Competition and Future Outlook - The market is viewed as a "marketplace of two products," with confidence in ZORYVE's competitive position against a recently approved PDE4 inhibitor [11] - Management believes investors may be underestimating the long-term potential of ZORYVE and the value of the pipeline, emphasizing the steroid conversion opportunity as a key growth driver [14]

Core Viewpoint - Arcutis Biotherapeutics has initiated a Phase 1a/1b clinical trial for ARQ-234, a novel biologic aimed at treating moderate to severe atopic dermatitis by targeting the CD200 receptor to regulate immune responses [1][3][4]. Group 1: Clinical Trial Details - The Phase 1a/1b study, ARQ-234-131, will enroll approximately 125 participants aged 18 to 65, including healthy volunteers and those with moderate to severe atopic dermatitis [4]. - The study consists of three parts: Part A focuses on single-ascending doses assessed at 16 weeks, Part B on multiple-ascending doses assessed at 30 weeks, and Part C on proof-of-concept expansion also assessed at 30 weeks [4][5]. - The primary objectives are to evaluate the safety and tolerability of ARQ-234 and clinical improvement in participants with atopic dermatitis, while secondary objectives include pharmacokinetics evaluation [5]. Group 2: Mechanism and Innovation - ARQ-234 is designed as a fusion protein that selectively activates the CD200 receptor, which plays a crucial role in regulating immune responses and restoring balance in immune function [2][7]. - The mechanism of ARQ-234 aims to reduce overactive immune responses, addressing critical unmet needs in the treatment of atopic dermatitis [3][7]. - Preclinical data indicate that ARQ-234 may have advantages over existing CD200R antibodies, including a longer half-life and a higher steady-state volume of distribution [8][9]. Group 3: Atopic Dermatitis Overview - Atopic dermatitis is the most common type of eczema, affecting approximately 16.5 million adults in the United States, characterized by chronic inflammation and significant impacts on quality of life [6]. - The disease manifests as a red, itchy rash and is associated with sleep disturbances and other quality-of-life issues across all ages [6]. Group 4: Company Background - Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on innovations in immuno-dermatology, with a commitment to addressing the needs of individuals with immune-mediated dermatological diseases [10]. - The company has a growing portfolio of advanced targeted therapies for inflammatory skin diseases, leveraging its dermatology expertise to develop differentiated treatments [10].

Summary of Arcutis Biotherapeutics FY Conference Call Company Overview - **Company**: Arcutis Biotherapeutics (NasdaqGS:ARQT) - **Industry**: Biotechnology, specifically focused on dermatological treatments Key Financial Highlights - **Q4 2025 Performance**: - Net revenue of **$127.5 million**, exceeding consensus by approximately **$15 million** [2] - Full-year revenue reached **$372 million**, indicating strong growth [2] - **29% quarter-over-quarter growth** in Q4 compared to Q3, with a **19% increase in demand** [8] Market Position and Strategy - **Market Share**: - Arcutis holds nearly **50% of the branded nonsteroidal market share** [3] - **Growth Strategy**: - Focused on three areas: growing the existing ZORYVE business, expanding its applications, and building the pipeline [4] - Plans to file an NDA for ZORYVE in infants aged 3 to 24 months in Q2 2026 [4] - Expansion of the dermatology sales force by **20%** to enhance market penetration [5] Product Development and Pipeline - **ZORYVE**: - Ongoing Phase II trials for additional indications such as hidradenitis suppurativa (HS) and vitiligo, with promising early results [5][6] - Anticipated approval for plaque psoriasis in children aged 2-5 by the end of June 2026 [20] - **ARQ-234**: - A novel treatment for atopic dermatitis expected to enter clinical trials soon, with potential to reset activated immune cells [6][68] Competitive Landscape - **Competitors**: - Recent approval of a PDE4 inhibitor is not seen as a significant threat due to its lower potency compared to ZORYVE [43] - **Market Dynamics**: - Shift in dermatology towards reconsidering the use of topical steroids, creating a favorable environment for ZORYVE [22] Regulatory and Coverage Developments - **Medicare Access**: - ZORYVE is now the only branded topical on the Medicare formulary, with access for about **one-third of Medicare lives** [19] - **Insurance Coverage**: - Strong commercial coverage with a single step through a steroid for most patients, enhancing market access [40] Financial Outlook and Profitability - **Cash Flow**: - Achieved cash flow breakeven last quarter, with expectations to maintain this status moving forward [49] - **Growth Projections**: - Potential for ZORYVE to reach **5%-20% of the 24 million prescriptions** written for its indicated conditions, translating to significant revenue growth [20] Investor Insights - **Underappreciated Aspects**: - The potential of ZORYVE as a multi-billion dollar product and the value of the pipeline opportunities are not fully recognized by investors [74] Conclusion - Arcutis Biotherapeutics is positioned for significant growth in the dermatology market with a strong product pipeline and strategic initiatives aimed at expanding its market share and enhancing patient access to its therapies. The company is optimistic about its future prospects, driven by ongoing clinical developments and favorable market dynamics.

Core Insights - Arcutis Biotherapeutics, Inc. is participating in the TD Cowen 46th Annual Health Care Conference from March 2-4, 2026, with a management fireside chat scheduled for March 2 at 1:50 p.m. ET, available via webcast for 180 days [1] - The company is recognized for its innovative treatments for immune-mediated dermatological conditions, with a portfolio of advanced topical treatments approved for three major inflammatory skin diseases and a strong pipeline targeting various inflammatory dermatological conditions [2] Stock Performance - H.C. Wainwright maintained a "Buy" rating for Arcutis on February 26, 2026, despite a recent stock price decrease, with the stock priced at $27.01 at that time and currently at $26.97, reflecting a decrease of 5.60% or $1.60 [3] - Over the past year, the stock has fluctuated between a high of $31.77 and a low of $11.86, with a current market capitalization of approximately $3.3 billion and a trading volume of 2,129,839 shares on NASDAQ, indicating active investor interest [4]

Company Overview - Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company focused on developing innovations for immune-mediated dermatological diseases [2] - The company has a growing portfolio of advanced targeted topicals approved for treating three major inflammatory skin diseases [2] - Arcutis utilizes a unique dermatology development platform and expertise to create differentiated therapies against biologically validated targets, resulting in a robust pipeline for various inflammatory dermatological conditions [2] Upcoming Events - Arcutis management will present at the TD Cowen 46th Annual Health Care Conference from March 2-4, 2026, in Boston [1] - The fireside chat is scheduled for March 2, 2026, at 1:50 p.m. ET, and the webcast will be accessible via the company's website [1]